TY - JOUR
T1 - Treatment options in patients with recurrent ovarian cancer
AU - Gadducci, Angiolo
AU - Conte, Pierfranco
AU - Cianci, Claudia
AU - Negri, Simona
AU - Genazzani, Andrea Riccardo
PY - 2001
Y1 - 2001
N2 - The majority of patients with advanced ovarian cancer need a second-line treatment for recurrent disease after surgical cytoreduction and first-line chemotherapy. In these patients, treatment planning is mainly dependent on the platinum-free-interval. The patients may be distinguished as platinum-refractory (progression under platinum-based therapy), platinum-resistant (relapse within 6 months), or platinum-sensitive (relapse after 6 months). Patients with platinum-refractory or-resistant disease should be encouraged to enter clinical trials. Alternatively, these patients could receive tamoxifen or a non-platinum single-agent therapy. Since response rate and duration to different single-agents are similar, patient convenience, toxicities from prior treatment, side-effects and costs play a role in the drug selection for salvage chemotherapy. Patients with platinum-sensitive disease should receive carboplatin based or carboplatin-plus paclitaxel-based regimens. Secondary surgical cytoreduction may have a role in highly selected patients with good performance status, with long disease-free interval and without extra-abdominal or liver metastases.
AB - The majority of patients with advanced ovarian cancer need a second-line treatment for recurrent disease after surgical cytoreduction and first-line chemotherapy. In these patients, treatment planning is mainly dependent on the platinum-free-interval. The patients may be distinguished as platinum-refractory (progression under platinum-based therapy), platinum-resistant (relapse within 6 months), or platinum-sensitive (relapse after 6 months). Patients with platinum-refractory or-resistant disease should be encouraged to enter clinical trials. Alternatively, these patients could receive tamoxifen or a non-platinum single-agent therapy. Since response rate and duration to different single-agents are similar, patient convenience, toxicities from prior treatment, side-effects and costs play a role in the drug selection for salvage chemotherapy. Patients with platinum-sensitive disease should receive carboplatin based or carboplatin-plus paclitaxel-based regimens. Secondary surgical cytoreduction may have a role in highly selected patients with good performance status, with long disease-free interval and without extra-abdominal or liver metastases.
KW - Chemotherapy
KW - Recurrent ovarian cancer
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=0035742616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035742616&partnerID=8YFLogxK
M3 - Article
C2 - 11848523
AN - SCOPUS:0035742616
VL - 21
SP - 3557
EP - 3564
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 5
ER -